13F reference period
Q2 2026
Security Snapshot
Arrowhead Pharma Inc - COM (ARWR) Institutional Ownership
CUSIP: 042797209
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
1
Shares (Excl. Options)
29
Price
$80.52
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COM
- Symbol
- ARWR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 29
- Total 13F value
- $2,335
- Portfolio coverage rank
- 0%
- Share change
- -104,879
- Value change
- -$6,575,397
- Number of holders
- 1
- SEC-reported price per share
- $80.52
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
1 identity field
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ARWR - Arrowhead Pharma Inc - COM is tracked under CUSIP 042797209.
- 1 institution reported positions in Q2 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 1 to 1 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$6.58M
Full value: $6,577,732 · USD · 31 Mar 2026.$2.34K
Full value: $2,335 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1 institution filings for Q2 2026.
Security key
042797209
13F reference period
Q2 2026
13F holders
1
13D/G owners
0
CIK / CUSIP context first
Open Q2 2026 holders
ARWR full holder history
ARROWHEAD PHARMACEUTICALS, INC. SEC filings
ARROWHEAD PHARMACEUTICALS, INC. company facts
ARROWHEAD PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 042797209:
As of 30 Jun 2026,
1
institutional investors reported holding
29
shares of
Arrowhead Pharma Inc - COM (ARWR).
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Headline period
Q2 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 29 | $2,335 | -$6,575,397 | $80.52 | 1 |
| 2026 Q1 | 104,908 | $6,577,732 | -$5,330 | $62.70 | 1 |
| 2025 Q4 | 104,993 | $6,970,485 | +$1,527,302 | $66.39 | 1 |
| 2025 Q3 | 81,988 | $2,827,766 | -$418,157 | $34.49 | 1 |
| 2025 Q2 | 94,112 | $1,486,970 | $15.80 | 1 | |
| 2025 Q1 | 94,112 | $1,198,987 | +$1,198,987 | $12.74 | 1 |
| 2021 Q4 | 0 | $0 | -$393,000 | $80.52 | 0 |
| 2021 Q3 | 6,000 | $393,000 | +$196,500 | $65.50 | 1 |
| 2021 Q2 | 3,000 | $248,000 | +$248,000 | $82.67 | 1 |
| 2020 Q2 | 0 | $0 | -$13,299,000 | $80.52 | 0 |
| 2020 Q1 | 462 | $13,299,000 | -$1,722,071 | $28785.71 | 1 |
| 2019 Q4 | 4,513 | $317,000 | +$254,000 | $93.15 | 2 |
| 2016 Q3 | 0 | $0 | -$3,000 | $80.52 | 0 |
| 2016 Q2 | 470 | $3,000 | -$87,304,000 | $6.38 | 1 |
| 2016 Q1 | 18,309,683 | $88,225,000 | -$23,838,795 | $4.82 | 72 |
| 2015 Q4 | 22,165,576 | $136,300,581 | -$20,832,888 | $6.15 | 95 |
| 2015 Q3 | 25,672,060 | $147,843,533 | -$9,695,531 | $5.76 | 100 |
| 2015 Q2 | 27,123,730 | $193,925,936 | -$28,553,407 | $7.15 | 93 |
| 2015 Q1 | 31,355,458 | $212,081,774 | -$28,991,059 | $6.77 | 87 |
| 2014 Q4 | 35,271,434 | $259,729,696 | -$131,887,765 | $7.38 | 98 |
| 2014 Q3 | 36,741,372 | $541,921,730 | -$33,054,305 | $14.77 | 109 |
| 2014 Q2 | 39,103,718 | $558,823,217 | -$8,990,936 | $14.31 | 111 |
| 2014 Q1 | 38,847,658 | $637,024,070 | +$251,556,697 | $16.42 | 98 |